首页膀胱肿瘤治疗及预后证据详情

Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer

原文: 2019 年 发布于 Front Oncol 201 卷 第 6 期 6415-6424 浏览量:246次

作者: Williams S. B. Hudgins H. K. Ray-Zack M. D. Chamie K. Smaldone M. C. Boorjian S. A. Daneshmand S. Black P. C. Kamat A. M. Goebell P. J. Seiler R. Schmitz-Drager B. Nawroth R. Baillargeon J. Klaassen Z. Kulkarni G. S. Kim S. P. Lee E. K. Holzbeierlein J. M. Hollenbeck B. K. Gore J. L.

作者单位: Department of Urology and Urological Oncology, Wroclaw Medical University, Wroclaw, Poland. Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland. Department of Public Health, Wrocław Medical University, Wrocław, Poland. Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland. Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. European Institute of Oncology, Milan, Italy. Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France. Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw, Poland.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.5152/tju.2021.21086

关键词: Biomarkers Tumor/*urine Cystoscopy/methods *DNA Methylation Humans Urinary Bladder Neoplasms/*diagnosis/urine biomarkers methylation molecular diagnostics neoplasms urinary bladder urine analysis

文献简介

BACKGROUND: Non-muscle invasive bladder cancer (NMIBC) is the most common bladder cancer. Many studies have reported that intra-arterial chemotherapy (IAC) combined with intravesical chemotherapy (IVC) could effectively reduce the recurrence rate of NMIBC. The purpose of this study is to assess the efficacy and safety of IAC combined with IVC for patients with high-risk NMIBC. METHODS: PubMed, Cochrane Library, Medline, Embase, Web of Science, and 4 Chinese databases will be searched for eligible studies published without language restrictions from their inception up August 31, 2019. Subgroup analysis will be mainly explored in study design, types of chemotherapy drugs, and sample size. Cochrane Collaboration Risk of bias Tool will be applied in evaluating the quality of enrolled articles. Statistical analysis will be carried out by the Stata version 14.0 software. RESULTS: The primary outcome is recurrence-free survival (RFS). The secondary outcomes include overall survival (OS), progression-free survival (PFS), adverse reactions and toxicity grade coded by common toxicity criteria for adverse events. CONCLUSION: The findings of this study will provide latest evidence to verify whether IAC combined with IVC is more effective and safer than IVC alone for patients with high-risk NMIBC. PROSPERO REGISTRATION NUMBER: CRD42019146847.

热门文献